| Entries |
| Document | Title | Date |
|---|
| 20110206766 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. | 08-25-2011 |
| 20090196922 | BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS - The present invention relates to a bilayer tablet which comprises a compartment containing a pharmaceutically acceptable simvastatin compound as its active ingredient; and at the same time a separate compartment containing a pharmaceutically acceptable lisinopril compound and a pharmaceutically acceptable folic acid compound as active ingredients, for the prevention of stroke in high-risk conditions or diseases. | 08-06-2009 |
| 20110189278 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20080233188 | Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide - The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof. | 09-25-2008 |
| 20130084333 | ABUSE RESISTANT ORAL DOSAGE FORMS - Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist. | 04-04-2013 |
| 20100074948 | METHOD OF PRODUCING FAST DISSOLVING TABLETS - A method of producing a fast-melt tablet comprises the steps of forming a mixture of components, the mixture comprising at least one fast dissolving sugar alcohol, at least one disintegrant or osmotic agent, and at least one an active component, blending the mixture for a period of time, and directly compressing the blended mixture at a compression force of typically between 5 and 2O kN to form the fast-melt tablet. The process of the invention does not involve any granulation step, thereby making the process more energy efficient and cost effective. The fast dissolving sugar alcohol is selected from the group comprising: mannitol; sorbitol; erythritol; xylitol; lactose; dextrose; and sucrose, and comprises at least 50%, preferably at least 60%, and more preferably at least 70%, of the tablet (w/w). The active component is suitably provided in the form of microparticles or microcapsules having an average diameter of less than 125 microns. Also described are directly compressed fast dissolving type tablets obtainable by the process of the invention. The tablets typically are flat-faced. | 03-25-2010 |
| 20120183610 | GLUCOCORTICOID THERAPY - The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects. | 07-19-2012 |
| 20120207831 | COATED SOLID DOSAGE FORMS - The invention is associated with ingestible film coated solid dosage forms comprising natural honey in the coating applied to such forms. The natural honey of the film coated solid dosage form is of sufficient level to be perceived by the user while avoiding sticking to each other or the packaging with which they are in contact and, or storage. | 08-16-2012 |
| 20130039982 | LOW-DOSE TABLETS AND PREPARATION PROCESS - The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterised in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste. | 02-14-2013 |
| 20100098756 | ORAL DISINTEGRATING TABLET - An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients. | 04-22-2010 |
| 20090136571 | PHARMACEUTICAL FORMULATIONS CONTAINING IRBESARTAN - The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally combined with a diuretic and to a process for the manufacture of said composition. | 05-28-2009 |
| 20100104637 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 04-29-2010 |
| 20130045276 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 02-21-2013 |
| 20100092553 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM - The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. | 04-15-2010 |
| 20130028971 | Pharmaceutical Compositions Comprising Rifaximin, Processes For Their Preparation And Their Use In The Treatment Of Vaginal Infections - The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided. | 01-31-2013 |
| 20130028972 | Tamper-resistant tablet providing immediate drug release - The invention relates to a tamper-resistant tablet comprising
| 01-31-2013 |
| 20130028973 | PARTICULATE COMPRISING A CALCIUM-CONTAINING COMPOUND AND A SUGAR ALCOHOL - The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets. | 01-31-2013 |
| 20130028974 | PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN - Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia. | 01-31-2013 |
| 20130089608 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs - The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and/or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions. | 04-11-2013 |
| 20090311321 | ORAL DISINTEGRATING TABLET HAVING MASKED BITTER TASTE AND METHOD FOR PRODUCTION THEREOF - The present invention provides an orally disintegrating tablet containing mitiglinide calcium hydrate. The tablet has reduced bitterness and quickly disintegrates in the mouth, while exhibiting rapid dissolution in the digestive tract. The bitterness-masked orally disintegrating tablet comprises: (a) mitiglinide calcium hydrate; (b) microcrystalline cellulose; (c) at least one masking agent selected from the group consisting of aminoalkyl methacrylate copolymer E, polyvinylacetal diethylaminoacetate, an ethyl acrylate-methyl methacrylate copolymer, and ethyl cellulose; (d) a sugar or a sugar alcohol; and (e) at least one selected from corn starch and partially pregelatinized starch. | 12-17-2009 |
| 20090304792 | GRANULE AND ORALLY DISINTEGRATING TABLET COMPRISING OXYCODONE - The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen. | 12-10-2009 |
| 20090304791 | SOLID ORAL FORMS OF EBASTINE - The invention relates to compositions in the form of matrices consisting of solid ebastine dispersions in nonionic surfactants having a HLB of between 10 and 20 and a melting point of between 30° C. and 70° C. The invention also relates to solid oral pharmaceutical forms of ebastine containing said matrices, particularly tablets, and having good solubility and bioavailability properties and improved stability. | 12-10-2009 |
| 20090117183 | ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME - The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and a binder such as hydroxypropylcellulose, but no lactose. Preferably the gestagen is dienogest, chlormadinone acetate, or levonorgestrel and the estrogen is ethinylestradiol, 17β-estradiol, or estradiol valerate. A method is provided for improving the prophylaxis of lactose intolerance in women taking oral contraceptives. The oral contraceptive preparations for a standard 28-day cycle or for long-term use contain at least 21 daily dose units of the gestagen and the estrogen in a low-dosage but without lactose and at most 7 daily dose units containing no active ingredient or a placebo. | 05-07-2009 |
| 20090041841 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS - Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation are disclosed. Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients suitable for controlled release formulations are disclosed. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. | 02-12-2009 |
| 20130071477 | NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE - There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain. | 03-21-2013 |
| 20130071476 | Rapid Melt Controlled Release Taste-Masked Compositions - Rapid melt tablets that dissolve and release an active component in the oral cavity are comprised of a pharmaceutical active ingredient such as dextromethorphan complexed with a resin that is effective in taste-masking the otherwise bitter taste of the active making it convenient for oral administration. The drug/resin-complexed particles can be coated with water swellable or water insoluble polymers to impart controlled release properties to the active ingredient. A rapid melt tablet also comprises diluents, sweeteners, flavors, disintegrants and other excipients to form granules that can be compressed into tablets at low pressure without the need for a binding agent. | 03-21-2013 |
| 20090092669 | STABLE IMATINIB COMPOSITIONS - Formulations containing imatinib, preferably imatinib mesylate, with high polymorphic stability and the processes for the preparation thereof are disclosed. | 04-09-2009 |
| 20130059004 | ORAL DRUG DELIVERY SYSTEM - An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces. | 03-07-2013 |
| 20130059005 | BUPROPION HYDROBROMIDE POLYMORPHS - Polymorphous and amorphous forms of bupropion hydrobromide are described. | 03-07-2013 |
| 20130059003 | SUSTAINED RELEASE DONEPEZIL FORMULATIONS - Sustained release formulations comprising donepezil, or its pharmaceutically acceptable salts, and methods of preparing the sustained release formulations. | 03-07-2013 |
| 20130095181 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIODIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 04-18-2013 |
| 20120189696 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME - A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more. | 07-26-2012 |
| 20130064890 | PHARMACEUTICAL FORMULATION BASED ON IBUPROFEN AND CODEINE HAVING IMPROVED STABILITY - Pharmaceutical formulation based on ibuprofen and codeine having improved stability. The invention consists of a novel pharmaceutical formulation having the form of tablets or similar comprising a core composed of an association of ibuprofen and codeine as active ingredients, together with an excipient including at least a diluent, a disintegrating agent, a fluidizing agent and a lubricant which is sodium stearyl fumarate. Said core is coated with a composition based on one or several polymers of diverse modified cellulose ethers and polymers derived from acrylic and methacrylic acids, a plasticiser and, an opacifier or colouring agent and any of the mixtures thereof. These characteristics render the tablets of the invention more efficacious and safe having the form of more stable preparations, without this fact implying greater technological complexity. | 03-14-2013 |
| 20130064891 | PHARMACEUTICAL COMPOSITIONS OF NSAID AND ACID INHIBITOR - The present invention relates a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients, wherein non-steroidal anti-inflammatory drug is present in two or more portions. More particularly, the invention relates to compositions comprising Esomeprazole and Naproxen and a process for preparation thereof. Further invention relates to a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients wherein, esomeprazole magnesium dihydrate and non-steroidal anti-inflammatory drug provides co-ordinated release. | 03-14-2013 |
| 20130115288 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 05-09-2013 |
| 20130064887 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases. | 03-14-2013 |
| 20130064888 | PHARMACEUTICAL FORMULATIONS - The present invention provides a pharmaceutical dosage form in the form of a tablet comprising: (a) a compressed inert core, (b) an optional subcoat over the compressed inert core, (c) a drug layer over the compressed core (a) or optional subcoat (b) comprising a drug having a water solubility at 25° C. of about 100 mg/l or less, a coating polymer and optionally a surfactant, and (d) optionally one or more layers coating the drug layer. The present invention also provides a process of making the same. | 03-14-2013 |
| 20130064889 | Tablet-in-tablet Palperidone Formulations and Methods for Production and Use Thereof - Tablet-in tablet paliperidone formulations and processes for preparation and use thereof are provided. | 03-14-2013 |
| 20090232889 | CRYSTALLINE SALTS OF QUINOLINE COMPOUNDS AND METHODS FOR PREPARING THEM - A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) | 09-17-2009 |
| 20090053309 | ADHESIVE COMPOSITIONS FOR THE TREATMENT OF XEROSTOMIA - Compositions and methods for the treatment of xerostomia are disclosed herein. Methods for making the compositions are also disclosed herein. The compositions are designed for individuals having the physiologic ability to salivate but who do not salivate in sufficient quantity to satisfy their personal comfort level of oral hydration. The compositions are typically in the form of a film or tablet, preferably in the form of a sticker tablet, most preferably in the form of a double layer sticker tablet, where one layer contains a bioadhesive material and the second layer contains the sialogogic agent and the one or more lipids. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions contain a therapeutically effective amount of one or more sialogogic agents and one or more lipids for treating xerostomia and a pharmaceutically acceptable bioadhesive carrier. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The methods for treatment of xerostomia require placing the composition on the oral mucosa of a patient's mouth, preferably on the palate or the cheek. The composition will adhere to the mucosal surface and dissolve over a period of time. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to 8 hours following administration to the buccal or oral mucosa. | 02-26-2009 |
| 20090011016 | Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion - Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa. | 01-08-2009 |
| 20090011015 | METHOD FOR PROMOTING SLEEP - Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The supplemental composition may include at least an extract of Valerian Root, an extract of Willow Bark and Melatonin or a derivative thereof. The supplemental composition may be provided for consumption at least one time daily, e.g., prior to sleep. | 01-08-2009 |
| 20090011014 | Tablet Formulation for Sustained Drug-Release - Disclosed is a pharmaceutical sustained release tablet for oral administration of a drug which is made of a compressed blend of at least three dry powders including a powder of a drug, a powder of a sustained release matrix for the drug, and a powder of at least one electrolyte. The sustained release matrix consisting of an un-cross-linked high amylose starch wherein the high amylose is substituted by at least one organic substituent comprising at least one carboxyl group. This organic substituent is preferably a carboxyalkyl having 2 to 4 carbon atoms, its salt or mixture thereof. This tablet has the advantage of having an improved integrity. | 01-08-2009 |
| 20130122090 | Multiple Unit Tablet Composition - A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer; at least two diluents and optionally one or more other pharmaceutically acceptable excipient, wherein one diluent is highly compactable microcrystalline cellulose and process for preparing the same. | 05-16-2013 |
| 20130122087 | ABUSE RESISTANT DRUG FORMULATION - A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting. | 05-16-2013 |
| 20130122088 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 05-16-2013 |
| 20130122089 | DPP IV INHIBITOR FORMULATIONS - The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus. | 05-16-2013 |
| 20110189281 | TELMISARTAN AND HYDROCHLOROTHIAZIDE COMBINATION THERAPY - A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of hydrochlorothiazide, and methods of treating hypertension in patients with such combination. | 08-04-2011 |
| 20110195119 | CONTROLLED RELEASE METFORMIN FORMULATIONS - Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration. | 08-11-2011 |
| 20080206328 | Hypocholesterolemic Compositions Comprising a Statin and an Antiflatulent Agent - The present invention relates to hypocholesterolemic compositions comprising statins plus antiflatulent agents. In particular the compositions of the present invention comprise a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, whether in free form or as pharmaceutically acceptable salts and hydrates thereof, plus an antiflatulent agent. selected from the group consisting of simethicone and dimethicone. The combination of statins plus antiflatulent agents is useful in the prevention and management of flatulence caused by statins. | 08-28-2008 |
| 20090022795 | Stable Pharmaceutical Formulation of an Acid Labile Compound and Process for Preparing the Same - The disclosed invention provides oral pharmaceutical formulations of an acid labile benzimidazole derivative comprising (a) a core comprising an acid labile benzimidazole derivative, (b) a seal coating layer, and (c) an enteric coating layer, wherein the core of the composition is devoid of any disintegrant. | 01-22-2009 |
| 20100291207 | PHARMACEUTICAL FORMULATION COMPRISING EZETIMIBE - The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 μm to 35 μm and d(0.5) of 3 μm to 20 μm, as well as methods for preparing said formulations. | 11-18-2010 |
| 20110142930 | Pharmaceutical Compositions of Atorvastatin - A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition. | 06-16-2011 |
| 20100233258 | TABLET HAVING CONCAVITY WITH ACTIVE INGREDIENT DISPOSED THEREIN AND MANUFACTURING METHOD THEREOF - The present invention provides a method of manufacturing tablets. An example of the method involves preparing a placebo blend containing only excipients. This placebo blend is compressed into tablets having concavities such as pinholes or indentations. Separately, a dispersion containing an active pharmaceutical ingredient, a drug, or a drug substance is prepared. A predetermined amount of this dispersion is placed into those concavities, and the tablets are dried. In this method, an active ingredient is handled in the form of a dispersion rather than as a solid. In addition, once the tablets are dried, the active ingredient is trapped inside the concavities and remains unexposed to external physical friction. As a result, human contact with powders or dust of active ingredient during the manufacturing and shipping processes may be minimized in a cost-effective manner. The present invention is also directed to the tablets prepared by this method. | 09-16-2010 |
| 20110135723 | PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN - The present invention provides pharmaceutical composition comprising pregabalin that is useful for once daily oral dosing. The present invention further relates to pharmaceutical composition comprising pregabalin that is useful for once daily oral dosing comprising pregabalin and on or more water insoluble components. The present invention preferably relates to a gastro-retentive tablet comprising pregabalin and one or more water insoluble component wherein water insoluble component preferably comprises of combination of ethylcellulose and hydrogenated castor oil. | 06-09-2011 |
| 20110086096 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION - The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients:
| 04-14-2011 |
| 20100143466 | MODIFIED RELEASE IBUPROFEN DOSAGE FORM - The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administering of a single dose. | 06-10-2010 |
| 20100272800 | ORALLY DISINTEGRATING OLANZAPINE TABLET - According to the present invention an orally disintegrating olanzapine tablet comprising magnesium stearate and sodium stearyl fumarate and one or more phramaceutically acceptable excipient in which the total weight of magnesium stearate and sodium stearyl fumarate is about 0.1 to 5% by weight of the total tablet and wherein the tablet disintegrates within up to 90 seconds in oral cavity is provided. | 10-28-2010 |
| 20100178338 | STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING ATORVASTATIN - This invention relates to stabilized pharmaceutical compositions comprising atorvastatin or pharmaceutically acceptable salts thereof, and processes for the preparation of the same. | 07-15-2010 |
| 20090142395 | DEFERASIROX PHARMACEUTICAL COMPOSITIONS - The present invention provides a process of preparing a high-load formulation of deferasirox with a sufficiently high dissolution rate and good bioavailability, which reduces the effect of the active material's physical characteristics on the chemical and physical properties of the final product. | 06-04-2009 |
| 20110274751 | TRIMETAZIDINE FORMULATION WITH DIFFERENT RELEASE PROFILES - A multilayered solid oral pharmaceutical formulation of trimetazidine or a pharmaceutically acceptable salt or polymorph of trimetazidine wherein one layer of said formulation provides controlled release, while the other layer provides immediate release. | 11-10-2011 |
| 20110300215 | TABLET FORMULATION OF EZATIOSTAT - Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet. | 12-08-2011 |
| 20100196471 | NOVEL TABLET DOSAGE FORM - The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients. | 08-05-2010 |
| 20110300214 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions. | 12-08-2011 |
| 20110274753 | DUAL RELEASE ORAL TABLET COMPOSITIONS OF DEXLANSOPRAZOLE - Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders. | 11-10-2011 |
| 20090246276 | Pharmaceutical Compositions - The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents across in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration. | 10-01-2009 |
| 20110052684 | PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration. | 03-03-2011 |
| 20080311193 | Sustained Release Formulation of Alprazolam - The present invention is directed towards the preparation of extended release Alprazolam formulation. The formulation thus obtained provides an efficient mode of delivery of Alprazolam in a continuous manner. | 12-18-2008 |
| 20080292697 | Direct compression polymer tablet core - The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: ( | 11-27-2008 |
| 20110287098 | DISSOLUTION STABILITY OF CALCIUM CARBONATE TABLETS - The present invention relates to a method for the preparation of a tablet comprising at least 50% w/w of calcium carbonate, the method comprising
| 11-24-2011 |
| 20100183717 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations of a core comprising a core active agent (e.g., alfuzosin) and a wax excipient substantially coated with an extended-release coating. | 07-22-2010 |
| 20080241237 | Pharmaceutical Compositions Comprising an Active Substance from the Substituted Benzhydrylpiperazine Family - The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions. | 10-02-2008 |
| 20100203126 | MULTILAYERED VITAMIN COMPLEX TABLET CONTAINING UBIDECARENONE - The present invention relates to a multi-layered vitamin/mineral complex tablet having enhanced stability of ubidecarenone. The present invention is characterized in that ubidecarenone is contained in a first layer, and ingredients decreasing the stability of ubidecarenone are contained in an additional layer separated from the first layer. The method is a convenient process, and the formulation prepared by the method can maintain a high content of ubidecarenone during long-term storage, thereby providing a simultaneous intake of ubidecarenone and nutritional ingredients such as various vitamins. | 08-12-2010 |
| 20110293717 | COMPACTED MOXIFLOXACIN - The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin. | 12-01-2011 |
| 20110293716 | PHARMACEUTICAL FORMULATION CONTAINING IBUPROFEN AND CODEINE - The invention consists of a new formulation of ibuprofen and codeine in the form of a tablet, which comprises L-leucine in a concentration ranging between 4%-15% as a lubricant, in order to prevent the formulation mixture from adhering to the punches and to other elements of the compression machine during the compression process. The new formulation additionally comprises talc (0.5%-5.0%) and silicified microcrystalline cellulose (30%-80%). The formulation is preferably arranged in the form of a core that comprises the active principles and, amongst others, the L-leucine, part of the talc and the silicified microcrystalline cellulose; this core is coated with a composition that contains a copolymer of methacrylic acid and ethyl acrylate. The tablets of the invention do not exhibit flaking problems, have an adequate hardness with a convenient attrition to allow for subsequent coating, offer disintegration values of less than 5 minutes, with dissolution values for both active principles in accordance with those specified for rapid-release tablets. | 12-01-2011 |
| 20110293715 | Pharmaceutical Formulation and Process for Its Preparation - The present invention relates to a multiparticulate tablet with improved gastro-protection comprising at least a pharmaceutically active substance in the form of enteric coated particles, and a mixture of tableting excipients, wherein the said mixture of excipients comprising xylitol and/or maltitol, each in a directly compressible form, a disintegrating agent, a lubricant and at least one other diluent and the ratio of a) the xylitol and/or the maltitol to b) the other diluent(s) is less than 5/95 (weight/weight) and the result of the “test of integrity of the film” is greater than 95%, preferably greater than 97% and more preferably still greater than 99% and the result of the “release test” is greater than 90%, preferably greater than 95%. According to one embodiment of the invention, the active substance is omeprazole or esomeprazole. According to another embodiment the tablet is a disintegratable tablet, which disintegrate in the mouth with or without chewing. The invention also comprises a process for preparing the claim tablet and its use in medicine. | 12-01-2011 |
| 20110111026 | HUMIDITY-RESISTANT DRUG FORMULATIONS AND METHODS OF PREPARATION THEREOF - The invention relates to a pharmaceutical composition of a humidity-sensitive core comprising an active ingredient or pharmaceutically acceptable salt thereof; a coating over the core, the coating containing a cationic polymer; and an additional coating over the cationic polymer-containing coating, with the additional coating including an acidifying agent. Also, methods for preparing such compositions wherein a cationic polymer containing coating is applied over a humidity-sensitive core that contains the active ingredient or pharmaceutically acceptable salt thereof; and then an additional coating is applied over the cationic polymer containing coating. | 05-12-2011 |
| 20090297598 | THERAPEUTIC COMBINATION - This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans. | 12-03-2009 |
| 20110189280 | DOSAGE FORM COMPRISING 1-ISOPROPYL-4-HEXAHYDRO-1H-1,4-DIAZEPINE OR A SALT THEREOF - The invention relates to a dosage form for oral administration comprising a carrier tablet, wherein the carrier tablet is at least partially (preferably partially) covered by a film comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine | 08-04-2011 |
| 20110142929 | SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992 - The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA | 06-16-2011 |
| 20110217373 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF GUANFACINE HYDROCHLORIDE - The present invention relates to an extended release pharmaceutical tablet composition comprising guanfacine comprising: a core containing guanfacine or a pharmaceutically acceptable salt thereof and one or more of pH-independent rate controlling polymer(s) and other pharmaceutically acceptable excipients; optionally a coating over the core as in (a) wherein, the coating comprises one or more of pH-independent rate controlling polymer(s). | 09-08-2011 |
| 20090022796 | Novel Substituted Benzimidazole Dosage Forms and Method of Using Same - The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor, including preparations of s-omeprazole, and at least one buffering agent. Also provided is a pharmaceutical composition comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules | 01-22-2009 |
| 20100112050 | Dosage Form For Insertion Into The Mouth - Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly anti-migraine agents to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract. | 05-06-2010 |
| 20110268799 | ORAL CONTROLLED RELEASE DOSAGE FORM - A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. | 11-03-2011 |
| 20090148522 | HEATED ROLLER COMPACTION PROCESS FOR MAKING PHARMACEUTICAL COMPOSITIONS - A process for using a heated roller compactor to prepare melt granulated composition of a therapeutic compound, especially a poorly compressible and/or moisture sensitive therapeutic compound, with a granulation excipient. | 06-11-2009 |
| 20100278913 | CHEWABLE TABLET - An excipient base for a chewable tablet comprising xylitol, sucralose and microcrystalline cellulose. The excipient base provides for an improved taste, stabilization, and mouthfeel qualities for the chewable tablet, as well as a greater likelihood for dosage compliance and use. The excipient base also enables the tablet to be directly compressible, free flowing and non-tacky, thus avoiding wet granulation techniques that can degrade the product and add to the cost of the manufacturing process. The excipient base also allows for the production of a chewable tablet that is suitable for administration to persons and animals having diabetes or hypoglycemia, and does not promote tooth decay or dental caries. | 11-04-2010 |
| 20120189695 | PHARMACEUTICAL DOSAGE FORM - This invention relates to a oral pharmaceutical formulation for methylphenidate or its analogs, derivatives, isomers or enantiomers, including d-threo-methylphenidate. | 07-26-2012 |
| 20120141586 | THROMBIN RECEPTOR ANTAGONIST AND CLOPIDOGREL FIXED DOSE TABLET - The present invention provides for a pharmaceutical formulation which comprises a) a compound of the formula (I): SCH 530348 or the bisulfate salt thereof; b) clopidogrel; and c) silicified microcrystalline cellulose. | 06-07-2012 |
| 20090311320 | MULTILAYER ORALLY DISINTEGRATING TABLET - This invention pertains to an orally disintegrating multilayer tablet wherein it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and optionally a pore-forming agent. | 12-17-2009 |
| 20120034302 | PARTICULATE COMPOSITION AND THE METHOD OF MAKING THE SAME - A particulate material for delivering an active ingredient and a method for making the same is provided. The particulate material can be included in a solid dosage form to provide both high tablet strength and smooth-dissolving mouth-feel. The particulate material includes at least two low moldability sugars, such as, dextrose and sucrose, in an amount of from about 70% to about 100% of the particulate material and is granulated in the presence of a binding agent. | 02-09-2012 |
| 20110027360 | PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS - Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning. | 02-03-2011 |
| 20100330176 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity - The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and pharyngeal cavity. | 12-30-2010 |
| 20110081415 | COATING APPARATUS - A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar coating layer, and a middle layer that includes a film component and a sugar coating component and is provided between the film layer and the sugar coating layer, wherein within the middle layer, the concentration of the sugar coating component at the interface between the middle layer and the sugar coating layer is higher than the concentration of the sugar coating component at the interface between the middle layer and the film layer. | 04-07-2011 |
| 20120087978 | DOSAGE FORMS OF APIXABAN - The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form. | 04-12-2012 |
| 20090087486 | Foam Wafer Containing a Polyvinyl Alcohol-Polyethyleneglycol-Graft Copolymer - Sheet-like dosage forms dissolving or disintegrating in an aqueous medium for releasing at least one active substance in a body orifice or body cavity. The sheet-like dosage forms comprise a polymer matrix in the form of a solidified foam containing spaces or cavities, as well as at least one pharmaceutical or cosmetic active substance. The polymer of the polymer matrix is a polyvinyl alcohol-polyethylene glycol graft copolymer. Methods for producing such dosage forms are also provided. | 04-02-2009 |
| 20100189784 | Use of Alkylphophocholine in Combination with Antitumor Medication for the Treatment of Benign and Malignant Oncoses in Humans and Mammals - The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. | 07-29-2010 |
| 20120107399 | PROCESS FOR DRYING OF BIBW2992, OF ITS SALTS AND OF SOLID PHARMACEUTICAL FORMULATIONS COMPRISING THIS ACTIVE INGREDIENT - The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by a water activity of the formulation of not more than 0.20 or a water content (Karl-Fischer) of not more than 4.2%. | 05-03-2012 |
| 20120107398 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and pioglitazone, processes for the preparation thereof, and their use to treat certain diseases. | 05-03-2012 |
| 20090263480 | TASTE-MASKED PHARMACEUTICAL COMPOSITIONS PREPARED BY COACERVATION - There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach. | 10-22-2009 |
| 20090162432 | Stable laquinimod preparations - The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. | 06-25-2009 |
| 20110200670 | Nicotine Containing Soft Gelatin Pastilles - The present invention relates to soft pastilles for nicotine replacement therapy, said pastille comprises about 0.05% to about 1% of nicotine active; about 5% to about 40% of gelling agent; about 30% to about 70% of plasticizer; about 0.05% to about 10% of sweetener; 0.5% to about 30% of releasing agent; about 0.05% to about 2% of preservative; about 0.01% to 5% of flavouring agent; and about 5% to about 20% of water. | 08-18-2011 |
| 20100124568 | PHARMACEUTICAL ARTICLES COATED WITH LUBRICIOUS COATINGS - The invention provides pills and tablets having lubricious coating deposited over the outer surface of the pills and the tablets. The coating comprises at least one hydrophilic polymer and at least one natural product, such as a natural polymer, a natural resin and/or a natural gum. | 05-20-2010 |
| 20080311196 | All Day Rhinitic Condition Treatment Regimen - A therapeutic regimen is disclosed. The regimen includes a first pharmaceutical dosage form comprising a first therapeutically effective amount of a first antihistamine and an anticholinergic agent; and a second pharmaceutical dosage form comprising a therapeutically effective amount of a second antihistamine and an anticholinergic agent. The second antihistamine either has greater H | 12-18-2008 |
| 20080206329 | Modified Release Ciprofloxacin Compositions - Controlled release tablets comprising ciprofloxacin, with hardness and friability of the said tablets ranges between 10 to 70 kiloponds and less than 2% respectively, the compositions releasing at least 80 percent of the total amount of the ciprofloxacin into a pH 1.2 aqueous dissolution medium within about 1 hour. | 08-28-2008 |
| 20110076326 | MODIFIED PROTEIN EXCIPIENT FOR DELAYED-RELEASE TABLET - The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic. | 03-31-2011 |
| 20090297599 | PHARMACEUTICAL COMPOSITIONS CONTAINING ROSUVASTATIN CALCIUM - A pharmaceutical composition is disclosed containing amorphous rosuvastatin calcium and at least one of the following stabilizing agents: magnesium hydroxide, calcium acetate, calcium gluconate, calcium glycerophosphate, or aluminum hydroxide, together with at least one pharmaceutically acceptable excipient. | 12-03-2009 |
| 20080213361 | Method for Production of Directly Compressible Ibuprofen Formulations - A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m | 09-04-2008 |
| 20120294940 | RAPIDLY DISINTEGRATING TABLET IN ORAL CAVITY - The present invention provides a method of suppressing the bitter taste of a drug when a rapidly disintegrating tablet in an oral cavity is produced. | 11-22-2012 |
| 20120294939 | DIRECT COMPRESSION FORMULATION AND PROCESS - Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile. | 11-22-2012 |
| 20110268798 | ORALLY DISNTEGRATING TABLETS FOR THE TREATMENT OF PAIN - An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients. | 11-03-2011 |
| 20100104636 | Pharmaceutical Compound and Composition - A pharmaceutical composition comprising rosiglitazone or a pharmaceutically acceptable salt thereof wherein said rosiglitazone has a median particle size diameter of about 5 microns to about 20 microns. | 04-29-2010 |
| 20090169621 | Pharmaceutical excipient having improved compressibility - A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide. | 07-02-2009 |
| 20080241238 | Controlled Release Coated Tablets Having Prolonged Gastric Retention - The present invention relates to a tablet composed of a core and a coating; said core is formed by two or more layers, wherein at least one of them contains an active agent ( | 10-02-2008 |
| 20080241236 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
| 20080241235 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
| 20100129443 | NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS - There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts. | 05-27-2010 |
| 20100129444 | Novel Pharmaceutical Formulations of Modafinil - The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof. | 05-27-2010 |
| 20080279934 | EXTENDED RELEASE FORMULATION FOR PRALNACASAN - This invention relates to a sustained release tablet comprising at least two layers, wherein at least one layer rapidly releases pralnacasan and the other layer releases pralnacasan in a delayed manner. This tablet is particularly suitable for the treatment of a condition such as autoimmune diseases, type I and type II diabetes, rheumatoid arthritis, osteoarthritis or psoriasis. | 11-13-2008 |
| 20080292696 | Enteric Sustained-Release Tablet Comprising Paroxetine - The present invention relates to an enteric, sustained-release tablet comprising paroxetine or a hydrates or anhydrides of a pharmaceutically acceptable salt thereof as active substance, more particularly to a tablet prepared by coating a sustained-release tablet core containing paroxetine with an enteric polymer, wherein the interaction between the tablet core and the enteric coating layer is minimized to enable constant drug release without regard to the residence time of the tablet in the stomach. | 11-27-2008 |
| 20080292698 | PHARMACEUTICAL COMPOSITIONS OF ISOLATED ORTHORHOMBIC CRYSTALLINE 4-[6-ACETYL-3-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENYLTHIO)PROPOXY]-2-PROPYLPHENOXY]BUTYRIC ACID AND METHODS OF USE - A pharmaceutical composition comprising a compound of formula (1) in polymorphic crystalline Form A: | 11-27-2008 |
| 20080305168 | In-Situ Melting and Gelling Tablet Composition For Oral Care - Disclosed herein is an oral care composition that provides pleasant cooling sensation and easy delivery of an oral care active ingredient. The tablet-type oral care composition of the present invention is prepared by compressing porous plastic granules at a pressure of 500 kg/cm2 or less and undergoes in situ melting and gelling by saliva or water in the buccal cavity, or by chewing. Upon direct administration of the composition to the buccal cavity, the composition undergoes melting and gelling by water or saliva, or by chewing action, and works to maintain oral health via gargling or mouth washing. Therefore, the formulation of the present invention advantageously reduces inconvenience of conventional liquid or ointment-like oral care products and also provides easy portability. | 12-11-2008 |
| 20080311197 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form. | 12-18-2008 |
| 20080206330 | Pharmaceutical Composition - Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity. | 08-28-2008 |
| 20100136112 | Oxidizing composition including a gel layer - A composition that generates and releases a biocidal solution comprising at least chlorine dioxide is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide, and a gelling agent that slows the rate of dissolution of the reactants, thereby increasing yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a sustained release. | 06-03-2010 |
| 20100136111 | PHARMACEUTICAL COMPOSITIONS OF DICLOFENAC AND MISOPROSTOL - The present invention relates to pharmaceutical compositions of diclofenac or pharmaceutically acceptable salts thereof and misoprostol or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparations of such compositions. | 06-03-2010 |
| 20090181084 | Oral fast-disintegrating tablet including particles of slowly-releaseable ascorbic acid - An oral fast-disintegrating tablet includes many tiny particles of slowly-releasable ascorbic acid, and a fast-disintegrating ingredient mixed with the many tiny particles that are dispersedly mixed with the fast-disintegrating ingredient. Each tiny particle is composed of a nucleus, an ascorbic layer and a release-control layer. The nucleus is coated with the ascorbic-acid layer and then with the releasing control layer to become a slowly-releasable particle. The tiny particles are mixed with the fast-disintegrating ingredient, which is composed of a mixture of ascorbic acid, water excipient, microcrystalline cellulose, a diluent agent, and disintegrant. So the tablet can be disintegrated swiftly in a mouth, and the tiny particles can enter the stomach and intestines with saliva to be slowly released, sustainingly absorbed by the organs. | 07-16-2009 |
| 20110014284 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising a SGLT-2 inhibitor, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders. | 01-20-2011 |
| 20110014283 | NOVEL DOSAGE FORM - The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurological and psychiatric disorders. | 01-20-2011 |
| 20110206767 | PHARMACEUTICAL COMPOSITION - The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
| 08-25-2011 |
| 20110268797 | MULTICOATED ALISKIREN FORMULATIONS - An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers. | 11-03-2011 |
| 20090181083 | Porous tablets as carriers for liquid formulations - A novel tablet product that in an easy, flexible and reproducible manner can be loaded with a relatively high amount of a pharmaceutically acceptable liquid formulation e.g. carrying a therapeutically, prophylactically and/or diagnostically active substance. The novel loadable tablet product may be produced in large-scale batches and stored until use and each batch or sub-batch may be loaded with the same or different pharmaceutically acceptable liquid formulations and/or active substances. A loadable tablet according to the invention has a porosity of 30% v/v or more. The invention also provides tablets that have been loaded with such a liquid formulation as well as a method for the preparation thereof. | 07-16-2009 |
| 20110142931 | SOFT TABLET CONTAINING DEXTROSE MONOHYDRATE - The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising directly compressible dextrose monohydrate and sucralose, said tablet being substantially fat free and said matrix being substantially free of non-saccharide, water soluble polymeric binders. | 06-16-2011 |
| 20110142928 | PROCESS FOR THE PRODUCTION OF CALCIUM COMPOSITIONS IN A CONTINUOUS FLUID BED - The present invention discloses a process for producing a particulate material comprising a calcium-containing compound, the process comprises granulating and/or coating a powder mixture, which comprises the calcium-containing compound together with one or more pharmaceutically acceptable excipients in a continuous fluid bed apparatus. | 06-16-2011 |
| 20120070495 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE - The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. | 03-22-2012 |
| 20080317852 | Pharmaceutical Combination - A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior art combination therapies. The invention also provides a pharmaceutical product containing the formulation. | 12-25-2008 |
| 20090142394 | Gastric Antacid - A novel particulate composite hydrotalcite which offers antacidic effect comparable to that of a particulate hydrotalcite so far used as a gastric antacid and, further, offers excellent stomach inner wall protection effect. A particulate composite hydrotalcite represented by the following formula (1), | 06-04-2009 |
| 20100151021 | Compositions Comprising Melperone - The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing melperone and/or a pharmaceutically acceptable salt, solvate, or ester thereof; a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation. | 06-17-2010 |
| 20080317853 | Mouth Dissolving Pharmaceutical Composition and Process for Preparing the Same - Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time. | 12-25-2008 |
| 20080317851 | IMMEDIATE RELEASE DOSAGE FORMS CONTAINING SOLID DRUG DISBURSIONS - High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility. | 12-25-2008 |
| 20080317854 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force. | 12-25-2008 |
| 20090208571 | Dosage form containing pantoprazole as active ingredient - Dosage forms for the oral administration of the magnesium salt of pantoprazole are described. | 08-20-2009 |
| 20110229569 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT - The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers. | 09-22-2011 |
| 20110223249 | EXTENDED RELEASE COMPOSITIONS COMPRISING MYCOPHENOLATE SODIUM AND PROCESSES THEREOF - Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases). | 09-15-2011 |
| 20090004268 | Methods and Compositions for Treatment of an Interstitial Lung Disease - Provided herein are methods of treatment of an interstitial lung disease (ILD) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof. | 01-01-2009 |
| 20090136570 | Taste-Masked Tablets and Granules - Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a pharmaceutically acceptable salt thereof, (b) a taste-masking polymer, (c) a superdisintegrant, and optionally other excipients. The carboxamide compound is an HIV integrase inhibitor, and the tablets and granules are suitable for use in the inhibition of HIV integrase, the treatment or prophylaxis of HIV infection, and the treatment or prophylaxis or delay in the onset of AIDS. | 05-28-2009 |
| 20100151020 | DRUG DELIVERY SYSTEM FOR ZERO ORDER, ZERO ORDER BIPHASIC, ASCENDING OR DESCENDING DRUG DELIVERY OF METHYLPHENIDATE - The invention is directed to a drug delivery device for controlled release of a drug, such as methylphenidate hydrochloride. The drug deliver device has a drug core, having a plug embedded therein, and at least a first coating that at least partially surrounds the core. The plug may be hollow or solid, and swells upon absorption of water, bursting through the first coating. The drag delivery device enables zero-order drug release profiles as well as more complicated release profiles to be obtained. | 06-17-2010 |
| 20110229568 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS - Described herein are peptide derivatives and peptidomimetics as inhibitors for transglutaminases, methods for their preparation, pharmaceutical compositions containing said compounds as well as uses of said transglutaminase inhibitors in particular for the treatment of coeliac disease and transglutaminase dependent diseases. | 09-22-2011 |
| 20100151018 | SUSTAINED-RELEASE LEVETIRACETAM COMPOSITION AND PREPARATION PROCESS - A subject of the present invention is a novel formulation of levetiracetam making it possible to obtain a solid pharmaceutical composition, particularly intended for oral administration, for the sustained release of levetiracetam. A subject of the invention is also a process for the preparation of such a pharmaceutical composition. | 06-17-2010 |
| 20100151017 | Oral Preparation With Controlled Release - A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour. | 06-17-2010 |
| 20100178340 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-15-2010 |
| 20100178339 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-15-2010 |
| 20100183716 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-22-2010 |
| 20100183715 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-22-2010 |
| 20100196472 | MODIFIED RELEASE COMPOSITIONS OF MILNACIPRAN - A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a T | 08-05-2010 |
| 20110059171 | ORAL GALENIC FORMULATION INCLUDING KETOROLAC AND B-COMPLEX VITAMINS, IN WHICH VITAMIN B6 IS IN AN OUTER LAYER SEPARATED FROM THE REST OF THE ACTIVE PRINCIPLES - The invention relates to a solid oral pharmaceutical composition combining ketorolac and B-complex consisting of inter alia thiamin, pyridoxine and cyanocobalamin (vitamins B1, B6 and B12 respectively) and/or the pharmaceutically acceptable salts thereof, as well as pharmaceutically acceptable excipients and/or vehicles. The invention also relates to the method for producing the composition and to the use of said composition having a synergistic therapeutic activity, indicated for the treatment of moderate to severe pain or neuralgias in different locations. | 03-10-2011 |
| 20100215740 | TASTE-MASKED ORALLY DISINTEGRATING TABLETS OF MEMANTINE HYDROCHLORIDE - The present invention relates to a solid pharmaceutical composition comprising memantine, which dissolves or disintegrates in the oral cavity preferably within about 60 seconds. The present invention further discloses orally disintegrating tablets of taste-masked memantine of optimal mechanical strength comprising memantine along with a taste-masking agent and pharmaceutically acceptable excipients. | 08-26-2010 |
| 20100255092 | COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ACCELERATED CONTROLLED ACTIVE SUBSTANCE RELEASE - The present invention relates to pharmaceutical or nutraceutical preparations comprising a) a core containing a pharmaceutically or nutraceutically active substance; and b) a controlling layer surrounding the core comprising i) 55 to 92% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of 80 to 98% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from Ci to C4 alkyl esters of (meth)acrylic acid and 2 to 20% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from (meth)acrylate monomers with a quaternary ammonium group in the alkyl radical; and ii) 8 to 45% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of more than 5 to 59% by weight based on the weight of the copolymer of structural units derived from acrylic acid or methacrylic acid, and to tablets and capsules containing same. | 10-07-2010 |
| 20100226981 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG - Sustained release oral dosage forms with a high loading of a gabapentin prodrug are disclosed. | 09-09-2010 |
| 20100226980 | NOVEL TABLET BASED ON S-ADENOSYL-METHIONINE - A subject of the invention is a tablet for pharmaceutical use, particularly for veterinary use, particularly suitable for the chronic treatment of hepatic insufficiency, comprising at least one S-Adenosyl-Methionine salt. Said tablet has the advantage of being divisible and being capable of including an appetizing agent. | 09-09-2010 |
| 20090017114 | Tranexamic acid formulations with reduced adverse effects - Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced. | 01-15-2009 |
| 20100221334 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME - Pharmaceutical compositions containing non-steroidal anti-inflammatory drugs (NSAIDs) and modified NSAIDs and leukotriene antagonists and methods for using such pharmaceutical compositions are provided herein. In a preffered embodiment naproxene 2-(methanesulfonyl)-ethyl ester is used in combination with Zileuton. | 09-02-2010 |
| 20100255090 | Controlled release matrix pharmaceutical dosage formulation - A compressed tablet of a pharmaceutical compound which contains uncoated pellets containing a pharmaceutical compound, where the uncoated pellets are dispersed in a matrix containing the pellets and a swellable polymer | 10-07-2010 |
| 20100221333 | Pellets Comprising a Core With a Water-Soluble Carrier - A pellet with a length/width ratio of less than about 1.4 is provided which comprises a core which comprises a water-soluble carrier and an active ingredient distributed homogeneously therein. The pellet disintegrates, with visually ascertainable loss of the pellet structure, into smaller fragments when the following test is carried out: (a) 200 to 800 mg of pellets are placed into a Petri dish with 0.5 ml of demineralized water. (b) The Petri dish is immediately afterwards fixed to the measuring cylinder holder of a stamping volumeter. (c) After 10 seconds, 30 stamping movements are carried out. (d) Immediately afterwards, the pellets are photographed. | 09-02-2010 |
| 20100143465 | PHARMACEUTICAL COMPOSITION - A pharmaceutical tablet or tablet layer comprising the angiotensin II receptor antagonist telmisartan in amorphous form, a basic agent and sorbitol, characterized in that the sorbitol has a specific surface area of between 0.75-3.5 m | 06-10-2010 |
| 20120195966 | ORAL DOSAGE FORM FOR MODIFIED RELEASE COMPRISING A JAK3 INHIBITOR - The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms. | 08-02-2012 |
| 20090074862 | LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME - The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep. | 03-19-2009 |
| 20090074863 | Dosage Forms Containing A PPI, NSAID And A Buffer - Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form. | 03-19-2009 |
| 20080311195 | BASIS PARTICLES, METHOD FOR MANUFACTURING THE SAME, AND ORALLY-DISINTEGRATING TABLET - A basis particle comprises a basic or acidic basis particle coated by a water-insoluble coating film, wherein the water-insoluble coating film contains a substance that is acidic with respect to the basic basis or basic with respect to the acidic basis. According to the basis particles (i.e., a main ingredient or an active drug)of the present invention, it is possible to temporarily adjust pH occurring in the immediate proximity of the basis particles by using a coating film, elution of the basis particles is suppressed and superior elution is exhibited without dependence on bodily pH. It is also possible to mask tastes such as the bitterness of the basis and it is possible to ingest drugs without sensing any bitterness. | 12-18-2008 |
| 20110104273 | GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE - Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described. | 05-05-2011 |
| 20110104272 | GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF ACETAMINOPHEN AND PHENYLEPHRINE - Compositions and methods for the treatment of a mammal suffering from pain and from nasal congestion or ophthalmic disorders are described. More specifically, a dosage form designed for release of acetaminophen and phenylephrine is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time. | 05-05-2011 |
| 20100297227 | PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ACTIVE AGENT AND A BINDER, WHICH SWELLS IN AN ACIDIC MEDIA - The invention relates to a pharmaceutical composition, which comprises at least one active agent and which further comprises a binder and/or a retarding agent, wherein the binder swells in an acidic medium, and the retarding agent retards the release of the active agent in an acidic or alkaline medium. | 11-25-2010 |
| 20090220594 | Tablet of Paracetamol Containing an Encapsulated Flavorant - A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink. | 09-03-2009 |
| 20100297226 | MULTIPLE UNIT PHARMACEUTICAL FORMULATION - An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer. | 11-25-2010 |
| 20110117193 | ANTIRETROVIRAL DRUG FORMULATIONS FOR TREATMENT OF CHILDREN EXPOSED TO HIV/AIDS - The present disclosure provides fast disintegrating formulations for the treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in patients such as neonatal, perinatal and pediatric children. Neonatal and perinatal formulations provide for the prevention or reduction of incidence of mother to child transmission of HIV. Also provided are formulations and methods for treating pediatric children having HIV/AIDS. The orally administered fast disintegrating formulations are in granule and tablet form and are specially formulation for children to increase adherence to treatment protocols. | 05-19-2011 |
| 20110117194 | PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER - The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time. | 05-19-2011 |
| 20110123617 | CLIOQUINOL FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - The present invention relates to compositions and methods for treating hematological malignancies and proliferative diseases, disorders and conditions involving increased D-cyclin expression. In particular, the present invention relates to compositions and methods for treating the hematological malignancies acute myeloid leukemia (AML) and multiple myeloma (MM) using clioquinol. | 05-26-2011 |
| 20100310651 | SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION - This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer. | 12-09-2010 |
| 20100310652 | COATED EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM - An extended release pharmaceutical composition comprising levetiracetam. A coated extended release pharmaceutical composition comprising levetiracetam wherein the core is coated with a rate controlling composition. | 12-09-2010 |
| 20100316708 | Novel Pharmaceutical Formulation Containing A Biguanide and a Thiazolidinedione Derivative - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 12-16-2010 |
| 20100323009 | Tablet composition for the in-situ generation of chlorine dioxide for use in antimicrobial applications - A solid composition in the form of a tablet that generates and releases a biocidal solution comprising at least chlorine dioxide with an enhanced weight percent yield is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide comprising a chlorite donor that is coated with a gel-forming material that slows the rate of dissolution of the high solubility chlorite donor, a free halogen donor, and an acid source, resulting in an unexpectedly high weight percent yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging and significantly increase the utility of the composition. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a controlled and sustained release. | 12-23-2010 |
| 20110008430 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-13-2011 |
| 20110111025 | High Drug Load Formulations and Dosage Forms - The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient. | 05-12-2011 |
| 20110008429 | Anti-Retroviral Combination - A pharmaceutical composition comprising a solid unit dosage form comprising:
| 01-13-2011 |
| 20110033536 | 24-HOUR SUSTAINED-RELEASE METOCLOPRAMIDE - The present invention consists of an extended-release metoclopramide hydrochloride pharmaceutical composition, in 30 mg drug substance 5 tablets, for use in gastrointestinal disorders. The formulation is mainly composed of a hydrophilic polymer, a hydrophobic polymer, a hydrophilic component and metoclopramide hydrochloride. The hydrophilic polymer is swollen by hydration when contacting water, forming a gel coat which controls drug substance release. The water inside the matrix dissolves the drug substance and this is diffused outside through the gel coat. The hydrophobic polymer shows plastic deformation properties under compression, tending to surround the drug substance particles reducing the pore quantity and dimensions in the matrix structure, delaying as a consequence the drug substance release. The hydrophilic component is part of the gel coating structure providing support thereto. Drug substance is the metoclopramide hydrochloride or a pharmaceutically acceptable salt thereof. | 02-10-2011 |
| 20110033533 | GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a roller compacted solid oral dosage form comprising a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, wherein the active ingredient is present in an amount of more than 38% by weight based on the total weight of the oral dosage form, as well as a process of preparing said solid oral dosage form. | 02-10-2011 |
| 20110033532 | AQUEOUS POLYMER DISPERSION BASED ON N,N-DIETHYLAMINOETHYL METHACRYLATE, ITS PREPARATION AND USE - The present invention relates to a process for preparing an aqueous polymer dispersion by free-radical emulsion polymerization of a monomer mixture which comprises N,N-diethylaminoethyl methacrylate, to the polymer dispersion obtainable by this process, and to the use thereof. | 02-10-2011 |
| 20110033535 | PHARMACEUTICAL COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF - The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition. | 02-10-2011 |
| 20110033534 | CONTROLLED RELEASE TAMSULOSIN HYDROCHLORIDE TABLETS AND A PROCESS OF MAKING THEM - The present invention relates to a controlled release preparation of tamsulosin hydrochloride comprising hydroxypropylcellulose and polyethylene oxide, and the process for making such pharmaceutical composition. | 02-10-2011 |
| 20110045068 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI - The present invention relates to pharmaceutical formulations comprising a layer of compressed granules to facilitate the administration of oral PPI. | 02-24-2011 |
| 20110236479 | DIRECT COMPRESSION FORMULATION AND PROCESS - Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile. | 09-29-2011 |
| 20100203125 | SYNERGISTIC ANTIBACTERIAL FORMULATION AND A METHOD OF MAKING THE SAME - An antibiotic formulation including penicillinase resistant penicillin, cefixime trihydrate, | 08-12-2010 |
| 20110250270 | Compositions containing a capillary-active system with application-relevant diffferentiability and their use - A composition that has a capillary-active system C optionally containing a capillary activator system CA consisting of drugs that increase blood flow, stabilize the vascular wall, and/or dilate the blood vessels; and/or a capillary-protective system CP comprising drugs for endothelial stabilization, lipoprotein protection, and for stabilization of leukocytes/platelets; and/or a capillary energy supply system CE comprising redox systems and cofactors in energy provision and energy carriers. This system C is combined with a selective action system S. The compositions are useful, systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components), or pharmaceutical agents. | 10-13-2011 |
| 20100055180 | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof - An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API. | 03-04-2010 |
| 20100062062 | Stabilized Coating for Pharmaceutical Formulations - A process is described for preparing stabilized tablet formulations for temperature and moisture sensitive active drugs. Water soluble polyvinyl alcohol is processed with drugs such as angiotensin converting enzyme (ACE) inhibitors and compressed into solid form once excess water is removed. Low dose polyvinyl alcohol ramipril tablets prepared by this process are stable under conditions of high humidity and heat for periods of at least up to six months with less than 8% hydrolysis of the prodrug to the active metabolite diketopiperazine (DKP). | 03-11-2010 |
| 20110177166 | Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation - The present invention relates to galenic formulations wherein the active ingredient aliskiren, preferably, a hemi-fumarate salt thereof, alone or in combination with another active ingredient, is melt-granulated and is present in an amount of more than 20% by weight based on the total weight of the oral dosage form, as well as a process of preparing said solid oral dosage form. | 07-21-2011 |
| 20110177165 | MULTIPARTICULATE TABLET AND METHOD FOR THE PRODUCTION THEREOF - A tablet, containing | 07-21-2011 |
| 20110250271 | SPACED DRUG DELIVERY SYSTEM - The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus. More particularly, the present invention provides a spaced drug delivery system that immediately releases one or more antidiabetic agents after oral administration of the system, and releases as a pulse one or more antidiabetic agents in a reliable manner at about a predetermined time after oral administration of the system. | 10-13-2011 |
| 20110150994 | Modified Release Formulation - The invention is directed to the use of an extended release tablet formulation for pramipexole. | 06-23-2011 |
| 20110070303 | NOVEL DOSAGE FORMULATION - The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I | 03-24-2011 |
| 20100028426 | TIME-SPECIFIC DELAYED/PULSATILE RELEASE DOSAGE FORMS. - A time-specific delayed/pulsatile release dosage form which comprises:
| 02-04-2010 |
| 20100003319 | RALOXIFENE IMMEDIATE RELEASE TABLETS - The present invention relates generally to formulations containing raloxifene or pharmaceutical salts thereof, as the active pharmaceutical ingredient and a process for preparing the same. | 01-07-2010 |
| 20080248110 | Pharmaceutical Compositions Useful in the Treatment of Pain - There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active ingredients are presented in particulate form upon the surfaces of the carrier particles, which carrier particles are larger in size than the particles of the active ingredients; and the bioadhesion and/or mucoadhesion promoting agent is, at least in part, presented on the surfaces of the carrier particles. | 10-09-2008 |
| 20080248111 | Orodispersible Tablets of Bitter Active Principles - The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO″), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules. | 10-09-2008 |
| 20090317463 | COMPOSITION FOR ORAL USE BASED ON S-ADENOSYLMETHIONINE AND A PROCESS FOR THEIR PREPARATION - The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide. The present invention also relates to the use of SAMe, or salts thereof, in combination with inositol and/or derivatives thereof with the possible further addition of melatonine, St. John's Wort and/or lemon balm for the treatment of depressive states and/or panic syndromes. | 12-24-2009 |
| 20090317462 | PEPTIDE PHARMACEUTICAL FOR ORAL DELIVERY - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 12-24-2009 |
| 20120201885 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE - This invention relates to a bilayer pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions. | 08-09-2012 |
| 20120201884 | EXTRACTS, FRACTIONS AND COMPOSITIONS COMPRISING ACETOGENINS AND THEIR APPLICATIONS - The current disclosure discloses acetogenin(s), extract(s)/fraction(s) standardized to acetogenin(s) comprising terminal α,β-unsaturated-γ-methyl-γ-lactone moiety derived from | 08-09-2012 |
| 20120201883 | ANTIVIRAL COMPOSITONS - A composition which includes a carboxamide, preferably ribavirin, for treating viral diseases in humans. A preferred embodiment of the subject invention comprises a very high dose (>600 mg) of ribavirin, and more preferably between about 800-1200 mg of ribavirin or more per dosage form. | 08-09-2012 |
| 20110256220 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 10-20-2011 |
| 20110256221 | PHARMACEUTICAL FORMULATIONS OF OLMESARTAN - This invention is related to pharmaceutical compositions, which have good flowability properties, comprising olmesartan medoxomil or combination of olmesartan medoxomil and hydrochlorothiazide and a lubricant or mixtures of lubricants and a pharmaceutically acceptable excipient or excipients. | 10-20-2011 |
| 20110165236 | CONTROLLED RELEASE HYDROGEL FORMULATION - Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as controlled release dosage compositions for hydrophobic active ingredients. In one aspect, the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a hydrophobic drug, an adjustable ratio of a non-cross linked hydrogel polymer and a non-gelling insoluble polymer. One example is a controlled release pharmaceutical composition which includes 1% to 80% of a therapeutically amount of cilostazol, 4% to 80% of a water-swelling hydrogel polymer, and 4% to 80% of a non-gelling insoluble polymer. In another aspect, a constant release profile of the pharmaceutical formulation is obtained. In another aspect, a zero degree release profile of the pharmaceutical formulation is obtained. Further, a method for treating intermittent claudication using the pharmaceutical formulation is provided. | 07-07-2011 |
| 20120121703 | TABLET CONTAINING FERRIC CITRATE - The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer. | 05-17-2012 |
| 20110165238 | STABILIZED ATYPICAL ANTIPSYCHOTIC FORMULATION - A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid. | 07-07-2011 |
| 20110165235 | DIRECTLY PRESSED ALISKIREN TABLETS - The invention relates to pharmaceutical compositions which contain the active agent Aliskiren and are suitable for the production of tablets by dry pressing, so that prior wet granulation can be obviated. The invention also relates to tablets which can be obtained by dry pressing of these pharmaceutical compositions and to a method for producing these tablets. The invention furthermore relates to the use of the novel pharmaceutical compositions and tablets for treating hypertension and illnesses associated therewith. | 07-07-2011 |
| 20110165237 | Protein Hydrolysate Excipients - A pharmaceutical composition comprising an effective amount of a pharmaceutical active and up to about 99.8% wt/wt water soluble protein hydrolysate to total weight of composition is provided. Whey protein hydrolysate is exemplary of a suitable soluble protein hydrolysate. A method for preparing such a composition is also provided. | 07-07-2011 |
| 20110020445 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM - Extended release pharmaceutical compositions of levetiracetam or pharmaceutically acceptable salts thereof in the form of a tablet comprising glyceryl behenate and a polymethacrylate polymer with at least one pharmaceutically acceptable excipient. | 01-27-2011 |
| 20110020446 | METHODS AND FORMULATIONS FOR MAKING PHARMACEUTICAL COMPOSITIONS CONTAINING BUPROPION - Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5% to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet. | 01-27-2011 |
| 20110027362 | TABLET HAVING IMPROVED ELUTION PROPERTIES - The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. | 02-03-2011 |
| 20110027358 | VALSARTAN TABLET FORMULATIONS - The present invention relates to a pharmaceutical tablet composition comprising an effective amount of valsartan. The tablet is prepared by wet granulation and exhibits satisfactory disintegration properties. The invention also relates to a process for preparation of a pharmaceutical tablet composition comprising an effective amount of valsartan wherein the process involves a wet granulation step. | 02-03-2011 |
| 20110027359 | Novel Pharmaceutical Compositions Comprising Levetiracetam - The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 02-03-2011 |
| 20100285124 | TETRAHYDROCYCLOPENTA[C]ACRIDINE DERIVATIVES AS KINASE INHIBITORS AND BIOLOGICAL - The invention relates to kinase inhibitors of the formula (I) in which —R | 11-11-2010 |
| 20100285123 | Controlled Release Dosage Formulation of Duloxetine - The preset invention provides a controlled release dosage form of duloxetine comprising a homogenous core comprised of duloxetine or its pharmaceutically acceptable salts, pharmaceutically acceptable polymeric carrier, solubility enhancer, a hydrophobic component, a hydrodynamic diffusion enhancer, a viscolyzing agent and pharmaceutically acceptable excipients; a entering coat on said core and a barrier layer between said core and the enteric coat. | 11-11-2010 |
| 20100330177 | PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR - Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof. | 12-30-2010 |
| 20110135724 | Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting - This invention is related to a pharmaceutical composition in the patient-friendly orally disintegrating tablet form comprising a weakly basic, selective serotonin 5-HT | 06-09-2011 |
| 20110262537 | EXTENDED RELEASE DOSAGE FORM OF ROPINIROLE - There is provided an extended release tablet in tablet dosage form of ropinirole or salts thereof comprising a) an inner tablet of ropinirole or salts thereof optionally with other pharmaceutically acceptable excipients and b) an outer tablet of other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising a core of ropinirole or salt thereof and outer mantle coating comprising one or more pharmaceutically acceptable excipients. The invention also relates to processes of preparing such compositions. | 10-27-2011 |
| 20100323008 | SOLID DOSAGE FORM COMPRISING A FIBRATE - The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations. | 12-23-2010 |
| 20100323007 | A POLYAMIDE RATE-MODULATED MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to a polyamide rate-modulated monolithic drug delivery system comprising at least one active compound and a biodegradable and biocompatible polyamide polymer. The polymer is selected for delivering, in use, the active compound, within a predetermined time frame depending on the biodegradable properties of the polymer, to a target organism or organisms. In one embodiment of the invention the polymer is modified by salting-out or crosslinking the polymeric material to achieve the desired biodegradability characteristics and, consequently, to control the release of the active compound. | 12-23-2010 |
| 20090175937 | Misuse Preventative, Controlled Release Formulation - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 07-09-2009 |
| 20110189277 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20110189275 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20100189783 | RELATING TO ANTI-HIV TABLET FORMULATIONS - An anti-HIV tablet formulation comprising a core containing 0.1 to 1.5% by weight (w/w) of colloidal silicon dioxide and 0.4 to 0.9% by weight (w/w) of a lubricant, the balance of the core comprising darunavir, a disintegrant and a filler comprising a spray-dried mixture of microcrystalline cellulose and colloidal silicon dioxide, the core being optionally coated with a film coating. | 07-29-2010 |
| 20110189279 | PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE PROPERTIES COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions with modified release properties comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and process of preparing such compositions. | 08-04-2011 |
| 20110189276 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20110135722 | PHARMACEUTICAL FORMULATION COMPRISING A PROTON PUMP INHIBITOR AND ANTACIDS - The present invention deals with a multiparticulate tablet, which disintegrates in the mouth containing: i) a proton pomp inhibiting agent, in particular of the benzimidazole type, in the form of enteric coated microgranules, which enteric coated granules are overcoated with at least one barrier coating, such as for instance a methacrylic copolymer-based protective film; ii) at least one antacid in the form of granules, for instance based on CaCO | 06-09-2011 |
| 20100323010 | FORMULATION AND PROCESS FOR DRUG LOADED CORES - The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core. | 12-23-2010 |
| 20100323011 | PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR - Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof. | 12-23-2010 |
| 20110038928 | ORALLY DISINTEGRATING TABLETS OF ZOLMITRIPTAN - The present invention is directed to a novel rapidly dissolvable pharmaceutical composition comprising zolmitriptan or pharmaceutically acceptable salts or esters thereof and least one direct compression filler. The pharmaceutical compositions of the present invention can advantageously be prepared in a solid dosage form, e.g. a tablet, utilizing directly compressible ingredients. | 02-17-2011 |
| 20100166857 | PHARMACEUTICAL DOSAGE FORMS AND METHODS OF MANUFACTURING SAME - The invention provides solid dispersions of at least one insoluble active pharmaceutical ingredient, pharmaceutical dosage forms comprising the solid dispersions, and methods of manufacturing same. In an embodiment, a solid dispersion of the present invention includes a plurality of coated particles comprising inert particles with a coating, wherein the coating comprises an insoluble active pharmaceutical ingredient dispersed in a hydrophilic polymer, and wherein the inert particles comprise nonpareils; and a plurality of granules comprising an insoluble active pharmaceutical ingredient with at least one pharmaceutically acceptable excipient. In an embodiment, the insoluble active pharmaceutical ingredient in the coating and the insoluble active pharmaceutical ingredient of the granules are the same type. A solid dispersion of the present invention may optionally be encapsulated in capsules or compressed into a tablet. Also disclosed are methods of making solid dispersions and methods of reducing plasma triglyceride and increasing high-density lipoprotein employing the solid dispersion. | 07-01-2010 |
| 20080311194 | Dispersible Tablets Comprising Deferasirox - The present invention pertains to a dispersible tablet comprising (a) Compound I of the formula | 12-18-2008 |
| 20110027361 | EXTENDED RELEASE DOSAGE FORM OF PALIPERIDONE - The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same. | 02-03-2011 |
| 20090110725 | SOLID, ORODISPERSIBLE AND/OR DISPERSIBLE COMPOSITION, WITHOUT AN EXCIPIENT OF KNOWN EFFECT AND ITS PROCESS OF PREPARATION - The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size not exceeding 50 μm; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 μm, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition. | 04-30-2009 |
| 20090291136 | Multiple Unit Tablets - The present invention relates to multiple unit tablets comprising multiple units compacted together with at least two tablet filler-binders and optionally other pharmaceutically acceptable excipients, wherein at least one of said tablet filler-binder is a tablet filler-binder having mean particle size-to-mean multiple unit size ratio from 10% to 40%, and at least one of said tablet filler-binder is a tablet filler-binder having mean particle size-to-mean multiple unit size ratio from 1% to 10%. | 11-26-2009 |
| 20120064159 | Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen - Multilayer tablets of a non-steroidal anti-inflammatory drug (NSAID) and/or acetaminophen for oral administration containing an immediate release layer or layers containing a NSAID and/or acetaminophen and/or a second therapeutic agent and an extended release layer containing a NSAID and/or acetaminophen are provided. Multilayer tablets containing an additional immediate and/or extended release layer of a second therapeutic agent are also provided. Methods for production of these multi-layer tablets and methods for their use in treating a subject in need of a NSAID and/or acetaminophen are also provided. | 03-15-2012 |
| 20090060995 | Dispersible sustained release pharmaceutical compositions - Disclosed herein are pharmaceutical compositions, in particular, dispersible compositions comprising sustained release granules of at least one active pharmaceutical ingredient and at least one release retard hydrophobic polymer formulated with super disintegrant and lubricant, to achieve dispersible and sustained release effect. | 03-05-2009 |
| 20120148672 | ABUSE RESISTANT OPIOID DRUG-ION EXCHANGE RESIN COMPLEXES HAVING HYBRID COATINGS - A sustained release formulation for opioid drugs is described. The formulation contains an opioid-ion exchange resin complex having a hybrid coating. The hybrid coating contains a cured polyvinylacetate polymer and a pH-dependent enteric coating layer mixed therein. Also provided are methods of making and using same. | 06-14-2012 |
| 20100159003 | PROCESS FOR THE PREPARATION OF A MEDICAMENT COMPRISING VARDENAFIL HYDROCHLORIDE TRIHYDRATE - The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C. | 06-24-2010 |
| 20110311624 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF - Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. | 12-22-2011 |
| 20120301547 | PALIPERIDONE DOUBLE-LAYERED OSMOTIC PUMP CONTROLLED RELEASE TABLET AND PREPARATION METHOD THEREOF - A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage. | 11-29-2012 |
| 20120301546 | ACID-RESISTANT SOFT GEL COMPOSITIONS - The present disclosure describes a delivery device for administration of nutraceuticals or pharmaceuticals, which device contains a soft gel shell comprising a gelatin-based water soluble film forming polymer, an acid insoluble polymer, and at least one reducing sugar and water, including processes, gel mixtures used for device production, and coatings containing such gel mixtures. | 11-29-2012 |
| 20080220060 | Gastroretentive Formulations and Manufacturing Process Thereof - The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation. | 09-11-2008 |
| 20080220059 | Pharmaceutical preparation of
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide - The invention relates to a pharmaceutical preparation for oral administration comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or its hydrates and/or solvates, as well as an acid, a method for its production as well as the use of this preparation for the treatment and/or prophylaxis of diseases which are caused by herpes viruses, in particular diseases which are caused herpes simplex viruses. | 09-11-2008 |
| 20090269401 | Controlled Release Solid Preparation - Disclosed is a solid preparation which comprises at least one active ingredient and at least one dissolution-controlling base substance and can be formed by compression molding, wherein the dissolution-controlling base substance contains 5.0 to 99.9% by weight (inclusive) of a modified starch having a moisture retaining capacity of 400% or more and a gel indentation load of 200 g or more, containing a water-soluble ingredient in an amount of 40 to 95% by weight, having particles passing through a 75 μm-mesh sieve in the proportion of 90% by weight or more and particles passing through a 32 μm-mesh sieve in the proportion of 20% by weight or more, and having an average particle diameter of not smaller than 20 μm and smaller than 50 μm. | 10-29-2009 |
| 20100330175 | CROSS-LINKED POLYALLYLAMINE TABLET CORE - A method and a composition for making a composition, tablet, or tablet core having cross-linked polyallylamine salts such as sevelamer hydrochloride, sevelamer carbonate, or colesevelam hydrochloride, that may be used for treating hyperphosphatemia or reducing cholesterol. The method involves blending of a cross-linked polyallylamine salt with a water soluble excipient, optionally with water, an additive and/or a lubricant, and further tableting the resulting blend to form tablets and tablet cores. | 12-30-2010 |
| 20100015221 | ORALLY RAPID DISINTEGRATING TABLET PREPARATION COMPRISING FAT-SOLUBLE ACTIVE INGREDIENTS - The present invention provides an orally rapid disintegrating tablet preparation that contains a high dose of a fat-soluble active ingredient, that exhibits excellent disintegration characteristics in the oral cavity, and that can be produced by a dry tabletting method. The present invention also provides a method of producing an orally rapid disintegrating tablet preparation. The present invention discloses an orally rapid disintegrating tablet preparation that is obtained by tabletting a uniform mixture prepared by mixing saccharide alcohol, crystalline cellulose, and a lubricant with a granule that has been produced by the adsorption of a fat-soluble active ingredient on a porous material. | 01-21-2010 |
| 20110064806 | SOLID COMPOSITIONS COMPRISING AN OXADIAZOANTHRACENE COMPOUND AND METHODS OF MAKING AND USING THE SAME - The invention provides solid compositions comprising (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid (OC-1) or a salt thereof and methods of making and using those compositions. The invention also provides the monohydrochloride salt of (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid. | 03-17-2011 |
| 20120156293 | ANTACID AND LAXATIVE TABLET - A tablet having excellent disintegration properties, as a tableted product, for a long time and has excellent shape-retention stability by the improvement of the strength of the tablet. The antacid and laxative tablet comprises magnesium oxide particles as the main component, wherein (a) the average secondary particle diameter measured by a laser diffraction scattering method of the magnesium oxide particles is 0.5 to 10 μm, (b) the content of the magnesium oxide particles is 85 to 96 wt %, (c) the content of crystalline cellulose as a binder is 2 to 8 wt %, (d) the content of croscarmellose sodium as a disintegrating agent-I is 0.8 to 2.5 wt %, (e) the content of insoluble polyvinyl pyrrolidone as a disintegrating agent-II is 1 to 3.5 wt %, and (f) the content of a lubricant is 0.5 to 2 wt %. | 06-21-2012 |
| 20110318413 | EXTENDED RELEASE FORMULATIONS CONTAINING DARIFENACIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof and one or more release controlling hydrophobic materials optionally coated with combination of one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials; wherein said formulation provides controlled release of the darifenacin over the period of 24 hours. The present invention further relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof, wherein darifenacin is incorporated in a matrix comprising one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials. | 12-29-2011 |
| 20110318412 | LOW DOSE DOXEPIN FORMULATIONS, INCLUDING BUCCAL, SUBLINGUAL AND FASTMELT FORMULATIONS, AND USES OF THE SAME TO TREAT INSOMNIA - The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep. | 12-29-2011 |
| 20100278912 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention further provides pharmaceutical dosage forms containing an active ingredient, and the pharmaceutical composition. The forms are adapted for immediate or controlled release of the active ingredient. The dosage forms may be used advantageously in the treatment of Parkinson's disease with levodopa and hyperactivity and attention deficit disorder with methylphenidate. | 11-04-2010 |
| 20110104271 | Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients - Compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. The recompactibility performance of such compositions is improved through the use of calcium phosphate having a relatively small particle size, e.g., a median particle size of not more than about 20 microns or not more than about 10 microns. | 05-05-2011 |
| 20080274178 | Orally Disintegrating Tablet - By mixing an active ingredient, crystalline cellulose, an inorganic excipient, carmellose, and a lubricant at not more than 0.8% by weight per tablet, and compressing the mixture, or compressing the mixture by an external lubricating method, a palatable orally disintegrating tablet which maintains a tablet hardness and exhibits good disintegrating property can be obtained. | 11-06-2008 |
| 20100151019 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF - A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration. | 06-17-2010 |
| 20120003309 | Solid Dosage Forms Of Bendamustine - In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. | 01-05-2012 |
| 20090074861 | STABLE TABLET CONTAINING DROXIDOPA - A tablet containing droxidopa as an active ingredient in a proportion of 20-80 wt % relative to the total weight of the tablet, and characteristically containing at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose, and corn-derived starch is provided. In addition, a preparation containing corn-derived processed starch or polyvinyl alcohol as a binder and the like, which is a stable tablet containing droxidopa as an active ingredient, is provided. | 03-19-2009 |
| 20120003310 | DELAYED RELEASE RASAGILINE FORMULATION - Disclosed are formulations of rasagiline base which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. Also, disclosed are rasagiline citrate salt and the use and process of manufacture thereof. | 01-05-2012 |
| 20090324714 | DUAL ADHESIVE TECHNOLOGY - A dual adhesive layer dosage form for delivery of active agent to and across, the mucosa is disclosed. Particularly, bioadhesive tablets for administration at the vaginal mucosa are disclosed as having a central active layer sandwiched between two bioadhesive layers. | 12-31-2009 |
| 20120009259 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES - The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. | 01-12-2012 |
| 20120009258 | COMPACTED CINACALCET - The invention relates to an intermediate, obtainable by jointly compacting (i) crystalline cinacalcet or a pharmaceutically acceptable salt thereof, with (ii) a hydrophilising agent, and also tablets containing the intermediates of the invention. The invention further relates to cinacalcet tablets with a bimodal pore size distribution and a method of preparing the tablets of the invention. Finally, the invention relates to the use of a pH adjuster for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 01-12-2012 |
| 20090004267 | Dosage Form with Impeded Abuse - A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm. | 01-01-2009 |
| 20120015029 | DIRECT COMPRESSION FORMULATION AND PROCESS - This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof, to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process for preparing the tablets by blending the active ingredient and specific excipients into the new formulations and then directly compressing the formulations into the direct compression tablets. The invention also relates to vildagliptin particle size distribution and a new crystal form of vildagliptin particularly adapted for the preparation of improved tablets and other pharmaceutical compositions. | 01-19-2012 |
| 20120015030 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured. | 01-19-2012 |
| 20120015028 | Controlled-Released Osmotic Pump Tablet with Lubricating Layer and the Preparation Thereof - An osmotic pump in form of controlled release tablet and the preparation thereof are disclosed Said tablet includes a double-layer tablet core consisted of a drug layer ( | 01-19-2012 |
| 20100255091 | ORAL FAST DISINTEGRATING TABLETS - The present invention refers to an orally fast disintegrable pharmaceutically acceptable multiple units tablet dosage form comprising a) tablet excipients comprising a disintegrant and b) individual units wherein each individual unit comprises:
| 10-07-2010 |
| 20120021054 | TABLET FORMULATION OF EZATIOSTAT - Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet. | 01-26-2012 |
| 20120064158 | DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL - A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine besylate by using said composition is also provided. | 03-15-2012 |
| 20120064157 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition. | 03-15-2012 |
| 20120114752 | STABLE TABLET CONTAINING 4,5-EPOXYMORPHINAN DERIVATIVE - The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient. | 05-10-2012 |
| 20120058183 | RETIGABINE TABLETS, PREFERABLY HAVING MODIFIED RELEASE - The invention relates to tablets, especially tablets with modified release, containing (a) retigabine and a combination of (b) water-soluble excipient and (c) non-water-soluble excipient; and a process for producing them. | 03-08-2012 |
| 20100247643 | Oral formulations - A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed. | 09-30-2010 |
| 20120027855 | PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY - The present invention relates to controlled release pharmaceutical formulations of active principle(s) like tetracycline-class antibiotics for providing increased residence time in the gastrointestinal tract and the process of preparing them. | 02-02-2012 |
| 20120027853 | PROCESS FOR PREPARATION OF ANTI-TUBERCULAR COMBINATION AND PHARMACEUTICAL COMPOSITION PREPARED THEREFROM - This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability. | 02-02-2012 |
| 20120027854 | PHARMACEUTICAL COMPOSITION COMPRISING EZETIMIBE AND SIMVASTATIN - The present invention belongs to the field of pharmaceutical industry and relates to a process for preparing dosage forms containing simvastatin and ezetimibe, comprising the steps of providing a first composition containing simvastatin, providing a second composition containing ezetimibe, and forming a dosage form comprising at least two separate compartments, wherein one compartment is formed using either the first or the second composition and another compartment is formed using the other composition. The present invention also relates to a process for preparing dosage forms containing simvastatin and ezetimibe, wherein the process involves a direct compression step. Furthermore, the present invention belongs to a dosage form obtained by this process, comprising at least two separate compartments, wherein one compartment contains simvastatin and one compartment contains ezetimibe. Finally, the present invention relates to a combination dosage form comprising a combination of simvastatin and ezetimibe present in two separate compartments of the dosage form. | 02-02-2012 |
| 20090081289 | PLANT AND A PROCESS FOR PRODUCTION OF TABLETS - The invention relates to a plant for production of tablets, a process for production of tablets and tablets as such. The plant comprises a mixing device producing a mixed liquid feed of active pharmaceutical ingredient and excipients. A spray dryer atomizes the mixed liquid feed and dried particles with a high flowability are produced. The dried particles are subsequently compressed to tablets in a tablet press. The invention possesses several advantages, including the possibility of using an auto mated rotary tablet press directly, thereby reducing the number of unit operations in the tablet production. | 03-26-2009 |
| 20110091547 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 04-21-2011 |
| 20110091546 | COMPOSITION FOR RAPID DISINTEGRATING TABLET IN ORAL CAVITY - The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness with compared to rapid disintegrating tablets of the prior art. | 04-21-2011 |
| 20120219622 | DPP IV INHIBITOR FORMULATIONS - The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus. | 08-30-2012 |
| 20100092552 | LOW DOSE CONTROLLED RELEASE TABLET - Low dose pharmaceuticals can be delivered for a prolonged period using a tablet-in-tablet design wherein the drug is contained in a controlled release matrix in the outer compression coating layer but not in the inner tablet core. | 04-15-2010 |
| 20100092551 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE - A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts:
| 04-15-2010 |
| 20100247644 | ADHESIVE COMPOSITIONS FOR THE TREATMENT OF XEROSTOMIA - Compositions for the treatment of xerostomia, and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a film or tablet, such as a double layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions themselves are able to increase the levels of saliva in the mouth without the need for active agents, such sialogogic agents. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa. | 09-30-2010 |
| 20100247642 | STABLE PHARMACEUTICAL FORMULATION FOR A DPP-IV INHIBITOR - A dosage form is provided for an anti-diabetic DPP-IV inhibitor of formula (I) as its tartarate salt, wherein the purity of the active pharmaceutical ingredient is maintained over a prolonged storage period under conditions similar to those likely encountered in home storage of the medication by a diabetic patient. A formulation free of calcium salts such as calcium phosphate, but including microcrystalline cellulose, copovidone, crospovidone, colloidal silicon dioxide, and magnesium stearate, when compacted into a tablet with the active pharmaceutical ingredient, was shown to be stable for at least six months at 40° C. and 75% relative humidity. Methods for preparation of the dosage form are also provided. | 09-30-2010 |
| 20120213850 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 08-23-2012 |
| 20100055179 | Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients - The present invention is directed to improved compositions and methods for preparing orally disintegrating tablets (ODTs). In one aspect of the present invention, the ODT further contains at least one active pharmaceutical ingredient (API). In another aspect of the present invention, the ODT contains a high load of at least one API. Specifically, the ODTs described in this invention containing a high load of API can accommodate up to about 70% w/w of active pharmaceutical ingredient in a unit dosage, while exhibiting the desirable attributes of fast disintegration time, acceptable hardness and friability for push through blister and bottle packages, and acceptable mouth feel. | 03-04-2010 |
| 20120164219 | PERORAL TABLET FOR BOWEL CLEANSING - To provide a peroral tablet for bowel cleansing which leaves no remains in the intestinal tract after bowel cleansing, which exhibits a dissolution property equivalent to that of conventional sodium phosphate-containing tablets including crystalline cellulose, and which is a small-size agent readily taken by a subject. | 06-28-2012 |
| 20120128773 | DESFESOTERODINE IN THE FORM OF A TARTARIC ACID SALT - The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic “R form”, as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form. | 05-24-2012 |
| 20120135076 | INTRABUCCALLY RAPIDLY DISINTEGRATING TABLET AND A PRODUCTION METHOD OF THE TABLETS - An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 μm, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape. | 05-31-2012 |
| 20100172980 | Tablet Containing Coated Particles of Cetirizine, Pseudoephedrine, and/or Naproxen - In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours. | 07-08-2010 |
| 20100172979 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations containing a core comprising a core active agent (e.g., levetiracetam) and a wax excipient, where the core is substantially coated with an extended-release coating. | 07-08-2010 |
| 20120219623 | PHARMACEUTICAL COMPOSITIONS COMPRISING BI-1356 AND METFORMIN - The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin. | 08-30-2012 |
| 20120251622 | CELLULOSE GUM AND POLYOL TROCHE - A troche with 2.5-6% cellulose gum and at least 75% polyol molecules is disclosed. It may be an adherent troche, preferably adhered to teeth or gums or cheek with acacia gum. Consumers are instructed to use the troches to relieve the sensations of dry mouth, particularly while sleeping. The polyol molecules are preferably xylitol. The troches may be made with a bi-layer tablet press rounded on one side and flat on the other, preferably using acacia gum in the flat side layer for adhesion. | 10-04-2012 |
| 20120251623 | METHOD OF ADMINISTERING AN ACTIVE INGREDIENT USING A CHEWABLE ORAL DOSAGE FROM COMPRISING TEXTURE MASKED PARTICLES - In one aspect, the present invention features a method of administering an active ingredient, said method comprising chewing an oral dosage form comprising a texture masked particle, said texture masked particle comprising a) a core containing an active ingredient; b) a first coating layer comprised of a taste masking agent that substantially covers the core, wherein said taste masking agent is comprised of an insoluble film forming polymer and a non-enteric, water soluble polymer; and c) a second coating layer on the surface of the first coating layer. | 10-04-2012 |
| 20120213851 | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN INTEGRASE INHIBITOR - Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described. | 08-23-2012 |
| 20080213360 | DRY GRANULATION BINDERS, PRODUCTS, AND USE THEREOF - A method for the preparation of microcrystalline cellulose containing tablets by roller compaction followed by tabletting is disclosed. A tablet formulation is converted to a dry granulate by roller compaction, and the dry granulate lubricated dry granulate and compacted to a tablet. The tablet formulation comprises at least one active, an microcrystalline cellulose containing material, and, optionally other pharmaceutically acceptable excipients. The microcrystalline cellulose containing material has a maximum primary compaction tensile strength of at least 9 MPa or at least 9.5 MPa and a secondary compaction tensile strength of at least 5 MPa, at least 5.5 MPa, or at least 6 MPa. A method for evaluating binders is also disclosed. | 09-04-2008 |
| 20120177734 | Delayed Release Tablet with Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 07-12-2012 |
| 20100272801 | PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND VALSARTAN - A single layer pharmaceutical composition comprising active agent(s) amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof wherein the composition exhibits bioequivalence to the commercially available bilayer tablet dosage form comprising amlodipine besylate and valsartan; when administered to human subject, under the bioequivalence parameters of a 90% Confidence Interval for AUC which is between 80% and 125%, and a 90% Confidence Interval for Cmax, which is between 80% and 125%. | 10-28-2010 |
| 20090060996 | Formulations of Clopidogrel Bisulphate - This invention relates to pharmaceutical tablet formulations of clopidogrel bisulphate which include glyceryl dibehenate as lubricant. The tablets are found to be very stable and to exhibit suitable dissolution characteristics. | 03-05-2009 |
| 20120258171 | COMPOSITION COMPRISING FESOTERODINE AND FIBER - The invention relates to a pharmaceutical composition containing (a) fesoterodine and/or fesoterodine metabolites and (b) fibers, wherein the weight ratio of components (a):(b) is in the range from 1:50 to 1:2; and oral dosage forms containing the pharmaceutical composition. The invention further relates to dry methods of preparing those dosage forms. | 10-11-2012 |
| 20120189693 | ORAL DOSAGE FORMS - Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm and comprises at least about 0.01 weight percent of at least one pharmaceutically active agent that is distributed substantially throughout said microtablet. Additional aspects of the present invention are directed to methods for producing compressed microtablets having a major dimension that is between about 0.25 mm and about 1.0 mm. | 07-26-2012 |
| 20120189694 | CO-PRECIPITATE COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR (PDE-5-INHIBITOR) AND A PHARMACEUTICALLY COMPATIBLE CARRIER, PRODUCTION AND USE THEREOF - The invention relates to a co-precipitate comprising a phosphodiesterase-5 inhibitor (PDE-5-inhibitor) and a pharmaceutically compatible copolymer carrier comprising 2 or more different acrylic acid derivatives, a method for production thereof and a medication comprising the co-precipitate according to the invention, a method for producing said medication and the use of said medication for treating an illness wherein the inhibiting of phosphodiesterase-5 is of therapeutic benefit. | 07-26-2012 |
| 20090022794 | Topiramate Tablet Formulation - The invention provides pharmaceutical compositions comprising as active ingredient topiramate, which are suitable for manufacturing tablet formulations by direct compression. The compositions preferably comprise spray-dried granulated mannitol and provide tablets of desired friability and hardness. | 01-22-2009 |
| 20120231077 | Coated Tablets, Their Method of Preparation, and Related Uses - A tablet comprising a tabletted core comprising a triglyceride granulate, and an enteric coating surrounding said tabletted core. In particular, a tablet wherein the tabletted core contains esterified omega-3 fatty acids such as eicosapentaenoic acid and/or docosahexaenoic acid. | 09-13-2012 |
| 20100226979 | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate - Disclosed herein a taste masked pharmaceutical composition suitable for oral solid dosage form comprising adsorbate of unpleasant or objectionable tasting active pharmaceutical agents and water insoluble polymer, wherein said active is first blended with an adsorbent such as magnesium aluminium silicate to achieve partially or significantly taste masking of said active and further granulated the resultant blend with water insoluble polymer to strengthen the taste masking without affecting the release of said active. | 09-09-2010 |
| 20080299193 | Pharmaceutical composition comprising eszoplicone - The present invention relates to a stable pharmaceutical composition of eszopiclone with a defined particle size. | 12-04-2008 |
| 20120237600 | MULTILAYER PHARMACEUTICAL COMPOSITION THAT CAN BE DISPERSED IN WATER AND WHICH CONTAINS A COMBINATION OF ANTIMALARIAL AGENTS - The present invention relates to a multilayer pharmaceutical composition that can be dispersed in water, containing one antimalarial agent in combination with at least one other antimalarial agent. The present invention also relates to a method for producing such a pharmaceutical composition. | 09-20-2012 |
| 20110002988 | ORALLY RAPIDLY DISINTEGRATING TABLET COMPRISING IMIDAFENACIN - Provided herein is an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. | 01-06-2011 |
| 20120263789 | DELAYED RELEASE RASAGILINE FORMULATION - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 10-18-2012 |
| 20110229570 | ORALLY RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR PRODUCING SAME - Disclosed is an orally rapidly disintegrating tablet characterized in that the tablet can be produced in a conventional tablet manufacturing facility and has a satisfactory level of hardness for practical applications, and the change in properties of the tablet (i.e., decreased in hardness of the tablet, and delay of the disintegration time of the tablet in the oral cavity) are rarely caused by factors such as humidity. The orally rapidly disintegrating tablet has hardness of 40N or more, can be disintegrated in the oral cavity within 60 seconds, and is produced by compressing of a mixture of (a) an active ingredient, (b) an excipient having good water wettability, (c) a water-insoluble polymer that is well compactible and does not substantially cause a decrease in the water wettability of the excipient and (d) a disintegrating agent. | 09-22-2011 |
| 20110236478 | CO-CRYSTALS AND PHARMACEUTICAL FORMULATIONS COMPRISING THE SAME - An immediate release formulation of an active ingredient. | 09-29-2011 |
| 20110236477 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. | 09-29-2011 |
| 20120276200 | FORMULATIONS OF QUINOLINONES - A pharmaceutical formulation, comprising: a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof, | 11-01-2012 |
| 20120276199 | TASTE MASKED PHARMACEUTICAL FORMULATIONS - The present invention relates to taste masked pharmaceutical formulations, processes for preparing the same and methods of using them. The present invention relates to taste masked effervescent formulations comprising fexofenadine or a pharmaceutically acceptable salt thereof, processes for preparing the same, and therapeutic uses and methods of treatment employing such formulations. | 11-01-2012 |
| 20110250272 | SOLID, ORODISPERSIBLE AND/OR DISPERSIBLE COMPOSITION, WITHOUT AN EXCIPIENT OF KNOWN EFFECT AND ITS PROCESS OF PREPARATION - The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size no exceeding 50 μm; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 μm, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition. | 10-13-2011 |
| 20110262538 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 10-27-2011 |
| 20120321710 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 12-20-2012 |
| 20110274752 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF DEXLANSOPRAZOLE - Modified release oral pharmaceutical compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof in the form of a bilayer tablet and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders. | 11-10-2011 |
| 20120282335 | RAPIDLY DISPERSING GRANULES, ORALLY DISINTEGRATING TABLETS AND METHODS - This invention relates to rapidly dispersing microgranules comprising at least one sugar alcohol or saccharide, at least one super disintegrant, and a pharmaceutically acceptable additive with multi-functionality (e.g., starch acting as a binder, disintegrant, diluent/filler, glidant, etc) at a low level, which can be formed by not only eliminating a wet milling step but also avoiding an extensive dry milling step. Furthermore, such rapidly dispersing microgranules could also comprise a pharmaceutically active agent thereby providing for a pharmaceutical composition, or the rapidly dispersing microgranules thus produced are suitable for blending with a pharmaceutically active agent that is optionally taste-masked and/or controlled release coated microparticles to also provide for a pharmaceutical composition and the invention is also directed to a method for manufacturing such rapidly dispersing microgranules in a high useable yield, as well as orally disintegrating tablets comprising such rapidly dispersing microgranules. The rapidly dispersing microgranules are also free flowing. | 11-08-2012 |
| 20120282336 | BILAYER TABLET FORMULATIONS - The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations. | 11-08-2012 |
| 20120093927 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 04-19-2012 |
| 20100215742 | DRUG ACTIVE IN NEUROPATHIC PAIN - The present invention relates to a compound of formula (I): in which: R is a linear or branched alkyl group containing between 1 and 3 carbon atoms, Y is CH or N, and p is an integer between 0 and 3 and preferably 0 and 1, and salts thereof, either acid-addition salts with a pharmaceutically acceptable organic or mineral acid, or base-addition salts with a pharmaceutically acceptable organic or mineral base. The invention also relates to a process for preparing the compound of formula (I), and to a pharmaceutical composition comprising it. The invention also relates to the use of an indazole for preparing a pharmaceutical composition that is active in the treatment of neuropathic pain. | 08-26-2010 |
| 20100215741 | PHARMACEUTICAL COMPOUNDS - Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): | 08-26-2010 |
| 20110311625 | Solid dosage forms of fenofibrate - An improved solid dosage form of fenofibrate which exhibits improved dissolution properties leading to increased bioavailability of fenofibrate. A novel core-shell approach to the composition is provided as well as a process for the preparation of the improved solid dosage forms. | 12-22-2011 |
| 20110311623 | COMPOSITION FOR MANUFACTURING ORALLY DISINTEGRATING DOSAGE FORM TO PROTECT COATING LAYER OF ACTIVE SUBSTANCE - The present invention relates to a composition for manufacturing an orally disintegrating dosage form that is used to prevent a coating layer of an active substance which is formed in a predetermined size in order to mask a bitter taste or an unpleasant taste. A predetermined ratio of an excipient having lower hardness than the coated active substance and another excipient having higher hardness and larger particle size than the active substance are used as means for protecting the coating layer from being destroyed. | 12-22-2011 |
| 20120100211 | MATERIAL AND PROCESS FOR INCORPORATION OF LOW DOSAGE ACTIVE PHARMACEUTICAL INGREDIENTS AND USE THEREOF - A low dose API pharmaceutical tablet having excellent content uniformity is provided. The tablet is formed by spray coating a support excipient with the API. The resulting composition is suitable for direct compression tablet formulation without the need for an additional granulation step to uniformly coat the API onto the support excipient. The support excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the support excipient components. | 04-26-2012 |
| 20120288563 | AMORPHOUS DARUNAVIR - Described herein is pure amorphous darunavir, methods of making pure amorphous darunavir and pharmaceutical compositions containing amorphous darunavir and a pharmaceutically acceptable excipient. | 11-15-2012 |
| 20100203127 | LARGE DOSE RIBAVIRIN FORMULATIONS - The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin. | 08-12-2010 |
| 20080299194 | Pharmaceutical Formulation For Producing Rapidly Disintegrating Tablets - A pharmaceutical formulation in the form of agglomerates comprising
| 12-04-2008 |
| 20130011477 | Stable Pharmaceutical Composition of Imatinib - The present invention relates to a compressed film-coated tablet comprising imatinib its pharmaceutically acceptable salts there of in an amount of more than 80% based on the total weight of the finished dosage form. | 01-10-2013 |
| 20130017262 | IMMEDIATE/DELAYED DRUG DELIVERYAANM Mullen; AlexanderAACI GlasgowAACO GBAAGP Mullen; Alexander Glasgow GBAANM Stevens; HowardAACI GlasgowAACO GBAAGP Stevens; Howard Glasgow GBAANM Eccleston; SarahAACI GlasgowAACO GBAAGP Eccleston; Sarah Glasgow GB - In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug. | 01-17-2013 |
| 20110159092 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING LINEZOLID AND PROCESS FOR PREPARING THE SAME - The present invention provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid or pharmaceutically acceptable salt, derivative, prodrug, metabolite and polymorph thereof and one or more pharmaceutically acceptable excipients and a process of preparing the same. The present invention further provides a method of treating bacterial infections in a mammal comprising administering an extended release, pharmaceutical composition suitable for once daily dosing comprising Linezolid capable of maintaining T>MIC for at least 24 hours. The present invention further provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid so that upon oral administration the maximum concentrations (C | 06-30-2011 |
| 20130022676 | PULSATILE DRUG RELEASE - In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a pulse at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a pulsed release of drug. | 01-24-2013 |
| 20130022678 | ORAL CONTROLLED RELEASE DOSAGE FORM - A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. | 01-24-2013 |
| 20130022675 | DRUG DELIVERY SYSTEM - A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. | 01-24-2013 |
| 20130022677 | DELAYED PROLONGED DRUG DELIVERY - In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a prolonged manner at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping, shortly before waking and continues to administer the drug during the early waking hours. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a prolonged release of drug. | 01-24-2013 |
| 20130022679 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 01-24-2013 |
